ENIOS APPLICATIONS IDIOTIKI KEFALAIOUCHIKI ETAIREIA

Their core work

ENIOS Applications is a Greek biotech SME working on molecular mechanisms that control cancer cell survival and death. Their research focuses on two interconnected pathways: the IRE1/unfolded protein response axis — a cellular stress system that cancer and neurodegeneration exploit for survival — and death receptor signaling, which governs how immune cells like natural killer cells trigger tumor cell death. In both MSCA-RISE consortia they joined, they contributed an industry-side drug design and therapeutic translation perspective alongside academic partners. Their practical value is identifying druggable targets within these stress and death pathways and bridging fundamental biology toward therapeutic applications.

What they specialise in

How they've shifted over time

Their first project (INSPIRED, 2017) placed them firmly in intracellular stress biology — IRE1, ER stress, UPR, autophagy — applied to cancer and neurodegeneration as drug targets. By their second project (DISCOVER, 2018), the focus shifted outward to the tumor-immune interface: death receptors, TRAIL, Fas ligand, and natural killer cells. This is a coherent progression: from understanding how stressed cancer cells resist death internally, to understanding how the immune system can be directed to kill them externally.

They are moving from intracellular stress biology toward tumor immunology, positioning themselves at the convergence of apoptosis research and cancer immunotherapy — one of the most active areas in current oncology drug development.

How they like to work

ENIOS operates exclusively as a consortium participant, never as coordinator — consistent with a small specialist company that brings targeted expertise rather than project management capacity. Both projects are MSCA-RISE, which involve multi-institutional staff exchanges, meaning they are comfortable with distributed, internationally mobile research teams. With 13 distinct partners across 8 countries from just 2 projects, they engage in genuinely diverse consortia rather than recycling the same network.

ENIOS has built connections with 13 unique consortium partners across 8 countries — a notably broad network for a two-project participant, reflecting the multi-partner structure of MSCA-RISE exchanges. Their collaborations span European academic and industry actors in cancer biology and drug development.

What sets them apart

ENIOS is a rare example of a Greek private SME active in fundamental cancer biology at the European level — most organizations in this space are universities or research institutes. Their industry status within MSCA-RISE consortia means they provide commercial drug development perspective that academic partners typically lack. Their specific niche — the crossover between cellular stress pathways and immune-mediated tumor killing — is directly relevant to next-generation cancer therapies being developed across Europe.

Highlights from their portfolio

• DISCOVER
  Highest EC funding (€193,500) and addresses death receptor signaling in tumor immune editing — a topic with direct relevance to immunotherapy drug development and NK cell-based cancer treatments.
• INSPIRED
  Anchors their foundational expertise in IRE1 and UPR targeting, covering both cancer and neurodegeneration, with an explicit drug design component that signals translational ambition beyond basic research.